Morgan Stanley on Sarepta’s CEO Switch: Clear Handover Is Positive, but DMD Challenges Linger
Michael Severino becomes Sarepta’s new CEO as Doug Ingram retires.
/ 18 items
#SRPT↓
Wolfe Research Upgrades Sarepta to Outperform as DM1 and FSHD Catalysts Approach
With key MAD data for DM1 and FSHD siRNA programs expected in H2 2026, SRPT stock shows strong growth potential.
Sarepta Moves Closer to Full Approval for Two Key Duchenne Muscular Dystrophy Drugs
Sarepta DMD drugs AMONDYS 45 and VYONDYS 53 near full FDA approval; decision due Feb 2027.
REGENXBIO Q1 Earnings: Revenue Miss Overshadows Positive Duchenne Gene Therapy Data
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
Sarepta Therapeutics Q1 2026 Earnings: Big Beat, But Stock Still Falls
Sarepta reported strong Q1 2026 earnings, with revenue of $730.8M, but shares fell as Elevidys sales dropped 46% due to label restrictions.
Eye Doctor and Fox News Regular Eyed as New Head of FDA Vaccine Division
FDA may pick Dr. Hemmati to lead CBER, which could speed up vaccine and biotech drug approvals, but decision is not final.